Procyon Advisors boosts Boston Scientific stake by 318% amid mixed analyst views and recall concerns

Procyon Advisors LLC increased its holdings in Boston Scientific Corporation by 318.1% in Q4, buying an additional 12,841 shares worth $1.6 million. Despite this, Boston Scientific faces mixed analyst ratings and concerns over an expanded recall of its Accolade pacemakers affecting 1.6 million devices, alongside legal and reputational risks. The company recently reported strong quarterly earnings with a 15.9% revenue increase, but ongoing challenges include battery issues and cautious price target revisions from several analysts. Investors should watch for further developments on recalls and legal matters impacting the stock's outlook.